Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Opdivo (nivolumab)
pCPA File Number:
21043
Negotiation Status:
Concluded with an LOI
Indication(s):
Classic Hodgkin's Lymphoma
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CADTH Project Number:
pCODR 10120
pCPA Engagement Letter Issued:
2018-10-09
Negotiation Process Concluded:
2019-10-04